EUVIMEDEUVIMED entdecken
Open Access

Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020

Nirmal Choradia, Fatima Karzai, Ryan Nipp iD, Abdul Rafeh Naqash, James L Gulley, Charalampos S Floudas iD

JNCI: Journal of the National Cancer Institute · 01.07.2024 · 116 (7) · 1063-1071

DOI: 10.1093/jnci/djae018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 19.02.2024. Verfasst von Nirmal Choradia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, National Cancer Institute (U.S.), Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural Research Program, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We described participant demographics for National Cancer Institute (NCI) clinical trials at the clinical center (NCI-CC participants) of the National Institutes of Health to identify enrollment disparities.

Methods

We analyzed NCI-CC data from 2005 to 2020, calculated enrollment fractions, compared with the US cancer population represented by the Surveillance, Epidemiology, and End Results cancer incidence data (2018) and the Cancer in North America database (2018), and compared further with clinical trial disparities data from the NCI Community Oncology Research Program and National Clinical Trials Network (2005-2019), and from ClinicalTrials.gov (2003-2016).

Results

NCI-CC (38 531 participants) had higher enrollment fractions for older adults (8.5%), male (5.6%), non-Hispanic (5.1%), and Black or African American (5.3%) participants; lower women proportion across race and ethnicity; and fewer female sex-specific cancer (6.8%) than male sex-specific cancer (11.7%) participants. NCI-CC had lower median age than Surveillance, Epidemiology, and End Results (54.0 vs 65.4); more Black or African American participants (12.0% vs 11.1%); and fewer women (41.7% vs 49.5%), White (76.1% vs 80.5%), Asian or Pacific Islander (4.6% vs 6.0%), American Indian or Alaska Native (0.3% vs 0.5%), and Hispanic participants (7.1% vs 13%). NCI-CC had more Black or African American and Asian or Pacific Islander participants; fewer Hispanic participants than the NCI Community Oncology Research Program and National Clinical Trials Network; more Black or African American and Hispanic participants; fewer Asian or Pacific Islander participants than ClinicalTrials.gov data. Improvement was noted for NCI-CC (older adults, Black or African American, Asian or Pacific Islander, Hispanic participants).

Conclusion

We found lower representation of older adults, women, Asian or Pacific Islander, American Indian or Alaska Native, and Hispanic participants vs the US cancer population and higher representation of Black or African American vs US cancer population and oncology clinical trials. Multifaceted efforts are underway to reduce disparities in cancer clinical trials at the NCI-CC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicNational Cancer Institute (U.S.)NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultDemographyEthnicityPatient SelectionSEER ProgramUnited StatesRacial Groups

Autor:innen und Institutionen

  • Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Ryan Nipp, Charalampos S Floudas

Förderung

  • Intramural Research Program
  • NIH HHS
  • NCI NIH HHS
  • CCR NIH HHS
  • Intramural NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • Center for Cancer Research

Zitieren

APA

Choradia, N., Karzai, F., Nipp, R., Naqash, A. R., Gulley, J. L., & Floudas, C. S. (2024). Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. JNCI: Journal of the National Cancer Institute, 116(7), 1063-1071. https://doi.org/10.1093/jnci/djae018

Vancouver

Choradia N, Karzai F, Nipp R, Naqash AR, Gulley JL, Floudas CS. Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. JNCI: Journal of the National Cancer Institute. 2024;116(7):1063-1071. doi:10.1093/jnci/djae018

BibTeX
@article{Choradia2024,
  author = {Choradia, Nirmal and Karzai, Fatima and Nipp, Ryan and Naqash, Abdul Rafeh and Gulley, James L and Floudas, Charalampos S},
  title = {Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {7},
  pages = {1063--1071},
  doi = {10.1093/jnci/djae018}
}
Kostenlos starten →